Get the marshmallows ready, the bonfire’s set to hit $1 billion at Mesoblast.
The Australian biotech, which investors have given plenty of lives via capital raisings in the past 10-years, could hit the $1 billion in cumulative cash outflows this reporting season for little evidence of a pathway to real revenue or profitability for shareholders.
Loading...
Anthony Macdonald is a Chanticleer columnist. He is a former Street Talk co-editor and has 10 years' experience as a business journalist and worked at PwC, auditing and advising financial services companies. Connect with Anthony on Twitter. Email Anthony at a.macdonald@afr.com
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
